Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial
글루코코르티코이드(CORTIVID)를 사용한 COVID-19 폐렴의 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] absolute difference
active cancer
Admission
age
allergy
ambient
approved
arterial blood
Barcelona
baseline
biochemical
Blinding
Block randomisation
block size
Blood
Breastfeeding
C-reactive protein
C-reactive protein (CRP
candidate
clinical
Clinical outcome
clinical outcomes
clinical trial
contraindication
Control
control group
Controlled trial
COVID-19
COVID-19 admission
COVID-19 pneumonia
criteria
death
decrease
defined
detect
Deterioration
Device
diabete
Diabetes Mellitus
diagnosis of SARS-CoV-2
discretion
dissemination
drug
drug treatment
early treatment
Effectiveness
element
elevated
eligible
emergency room
ethics committee
EudraCT
exclusion criteria
expected
explained
ferritin
Follow-up
followed by
following
glucocorticoid
Glucocorticoids
groups
hospital
Hospital admission
hypertension
ICU
Identifier
IL-6
immunosuppressants
IMPROVE
inclusion criteria
independent
Infection
inflammatory biomarkers
Informed consent
intensive care
intensive care unit
interleukin
interleukin-6
Intervention
intervention group
intravenous
intravenous infusion
Laboratory
Loading dose
Lopinavir
Lopinavir/ritonavir
maintenance dose
management
manic
manic disorder
mechanical ventilation
Medical devices
Medicine
Medicines
Methylprednisolone
Nasopharyngeal swab
nasopharyngeal swabs
number
objective
outcome
outcome assessor
outcome assessors
Outpatient
oxygen
oxygen saturation
PaO
parallel-group
partial pressure
Partial pressure of oxygen
participant
Patient
patient age
patients
patients with COVID-19
Pharmacy
Placebo
Pneumonia
polymerase chain
Potential
Pregnancy
primary endpoint
Primary outcome
procalcitonin
proportion
protocol
Psychiatric
Psychological
psychotic
pulse
Pulses
Quadruple blind
radiological
random
randomisation
randomised
randomised controlled trial
randomizeR
receive
recommendation
recruit
recruitment
Registered
Remdesivir
required
researcher
reverse transcriptase
Reverse transcriptase polymerase chain reaction
Ritonavir
RT-PCR
Sample size
SARS-CoV-2
SARS-CoV-2 pneumonia
sequence
Spain
Spanish
sputum
Standard of care
status
stratified
study outcomes
Study protocol
supplementary material
Symptom
Tablet
the patient
therapy
title
total sample size
transcriptase
Treatment
treatment failure
Trial
Trial registration
two group
two groups
two-tailed
type I
type II error
uncontrolled hypertension
unit
university
Version
website
with COVID-19
[DOI] 10.1186/s13063-020-04999-4 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04999-4 PMC 바로가기 [Article Type] Letter